Peter Thompson Sells 115,844 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 115,844 shares of the business’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total value of $5,270,902.00. Following the transaction, the director owned 2,555,877 shares of the company’s stock, valued at $116,292,403.50. The trade was a 4.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Price Performance

Shares of NASDAQ:SION opened at $43.99 on Friday. The company has a market capitalization of $1.99 billion, a price-to-earnings ratio of -22.79 and a beta of 1.33. The firm’s 50 day simple moving average is $39.85 and its 200 day simple moving average is $39.53. Sionna Therapeutics, Inc. has a fifty-two week low of $16.38 and a fifty-two week high of $48.44.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). Equities research analysts expect that Sionna Therapeutics, Inc. will post -2.57 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on SION shares. Citizens Jmp reissued a “market outperform” rating and issued a $63.00 price target on shares of Sionna Therapeutics in a report on Tuesday, May 26th. Freedom Capital downgraded Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 20th. Stifel Nicolaus raised their price objective on Sionna Therapeutics from $44.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, May 18th. BTIG Research reiterated a “buy” rating and set a $58.00 target price on shares of Sionna Therapeutics in a report on Wednesday, May 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Friday, May 8th. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $53.22.

Institutional Trading of Sionna Therapeutics

Hedge funds have recently bought and sold shares of the stock. Deutsche Bank AG boosted its holdings in shares of Sionna Therapeutics by 4.5% in the fourth quarter. Deutsche Bank AG now owns 10,029 shares of the company’s stock valued at $413,000 after buying an additional 433 shares during the period. Bank of America Corp DE raised its holdings in shares of Sionna Therapeutics by 8.8% during the third quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock worth $192,000 after acquiring an additional 529 shares during the period. MetLife Investment Management LLC raised its holdings in shares of Sionna Therapeutics by 6.6% during the fourth quarter. MetLife Investment Management LLC now owns 8,565 shares of the company’s stock worth $352,000 after acquiring an additional 532 shares during the period. BNP Paribas Financial Markets lifted its position in Sionna Therapeutics by 35.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company’s stock valued at $70,000 after acquiring an additional 619 shares in the last quarter. Finally, GF Fund Management CO. LTD. bought a new stake in Sionna Therapeutics in the 4th quarter valued at $36,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.